Navigation Links
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc. (NASDAQ: AGEN) today announced an oral presentation of updated data from a Phase 1/2 investigator-sponsored trial of the company's investigational cancer vaccine Oncophage(R) (vitespen) in recurrent, high-grade glioma at the 75th annual meeting of the American Association of Neurological Surgeons (AANS; abstract #606). Preliminary results from the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline (P less than .001), as determined using three separate immune response assessments. Of the 12 patients treated, four continue to receive Oncophage and eight have completed treatment and are evaluable for overall survival. Seven of these eight evaluable patients have exceeded the historical median benchmark of 6.5 months survival from time of recurrence.

"In this trial we have observed a correlation between immune response as a result of Oncophage vaccination and potential clinical benefit," said Andrew T. Parsa, MD, PhD, assistant professor in the department of neurological surgery at the University of California, San Francisco, and recipient of the 2007 Young Investigator Award at AANS. "Understanding that the patients in this trial represent the most challenging patient population to treat, we are highly encouraged by the prolonged improvement in overall survival compared with historical controls."

Commenting on the paper presented at AANS, Henry Brem, MD, director of neurosurgery at Johns Hopkins, noted, "This is an encouraging study of a therapeutic cancer vaccine that targets multiple tumor antigens, supported by rigorous immunomonitoring. A larger Phase 2 trial is certainly warranted to evaluate efficacy." Dr. Brem is a developer of Gliadel(R) Wafer (polife prosan 20 with carmustine implant, MGI Pharma), the first approved local therapy for glioma.

Derived from each individual's tumor, Oncophage contains the 'antigenic fingerprint' of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been granted fast track and orphan drug designations from the US Food and Drug Administration (FDA) in both metastatic melanoma and renal cell carcinoma.

Study Findings

The investigator-sponsored Phase 1/2 study is designed to evaluate the feasibility, safety and activity of Oncophage vaccination in patients with recurrent, high-grade glioma. The trial involves two cohorts of six patients, both receiving a minimum of four Oncophage injections: the first cohort receives biweekly vaccinations; the second cohort receives weekly vaccinations. Patients are monitored for immune response before and after Oncophage treatment using three different techniques.

According to investigators, no adverse events or toxicity identified were considered attributable to the vaccine. A tumor-specific immune response was detected after vaccination in all 12 patients. The investigators will continue to follow patients for overall survival. Researchers plan to present further results from the Phase 1/2 trial of Oncophage in late 2007 and submit the findings for peer-review publication. Based on these results, the Phase 2 portion of this study is expected to move forward in mid-2007.

"Our goal is to change the management of recurrent glioma from a life threatening disease, in which survival rates are typically 25 to 26 weeks, into a chronic disease with extended survival and improved quality of life for patients," said Dr. Parsa. "Alth ough our survival data are encouraging, a larger Phase 2 study will be required to determine the benefit of Oncophage for patients with recurrent glioma. The consistent, tumor-specific immune response seen in these patients suggests that in the right patient population, Oncophage could have a significant impact."

About Brain and Spinal Cord Tumors

Glioma is a cancer affecting the central nervous system that begins in glial cells (connective tissue cells that surround and support nerve cells). Malignant glioma is currently a fatal disease. The American Cancer Society estimates that 20,500 malignant tumors of the brain or spinal cord will be diagnosed during 2007 in the United States, and that about 12,740 people will die from these tumors. Brain and spinal cord tumors account for about 1 percent of all cancers and 2 percent of all cancer-related deaths.

About UCSF

UCSF is a leading university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in the life sciences, and providing complex patient care. For more information, please visit

About Antigenics

Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company's investigational product portfolio includes Oncophage(R) (vitespen), a patient-specific therapeutic cancer vaccine being evaluated in several indications; Aroplatin(TM) (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21, an adjuvant being evaluated by Antigenics' corporate partners in several late-stage clinical trials. For more information, please visit

This press release contains forward-looking information, including statements regarding the potential safety and activity of Oncophage in patients with glioma, publication plans and future clinical t rials. These risks and uncertainties include, among others, the risk that a small investigator-sponsored study in 12 patients is not representative of what will be shown in larger trials that could support registration; and the factors described under Factors That May Impact Future Results in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics' Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 16, 2007. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.


Antigenics Inc.
Sunny Uberoi, 917-443-3325
Media Relations
Robert Anstey, 800-962-2436
Investor Relations


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... the launch of Radiology Solutions, a fully integrated, ... Solutions comprises customized, data-driven practice management approaches that ... help radiology practices improve care delivery and reduce ... Radiological Society of North America Annual Meeting (RSNA) ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North ... and distribution of radiopharmaceuticals, announced that as of January ... Inc. (Zevacor Pharma). The decision to rebrand the company ... firm as well as its close relationship with Zevacor ... Illinois Health and Science (IHS). Peter ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, 2015 ... Public Research (the Institute) announced today that it ... a medical device start-up company with technology developed at ... based on publicly-funded research, and bridges early funding gaps ... -based universities and research institutions. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... During the National Family ... and held two webinars on topics of ‘Medical and Palliative Care Decisions,’ and ... . , With a loved one's diagnosis of mesothelioma, the closest ...
(Date:11/30/2015)... ... 2015 , ... Thermi™, a world leader in thermistor-regulated energy ... temperature controlled radiofrequency platform has received CE marking and may now be sold ... as a clinical endpoint. The technology has been available in the United ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... driverless vehicle experience this summer, ushering in a new era of publicly accessible ... and electric shuttle, will continue to offer guests an up-close look at the ...
(Date:11/30/2015)... Creek, Michigan (PRWEB) , ... November 30, 2015 , ... ... MI, the American Cancer Society held an annual fundraising event, a 5K walk known ... a holistic treatment center for substance abuse which is also located in Battle Creek, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... off its annual fundraising campaign to raise funds for its research, education, support, ... 10% of the organization’s annual funding. , The Mesothelioma Applied Research Foundation, which ...
Breaking Medicine News(10 mins):